Skip to main content

Sphingolipids in Anticancer Therapy

Buy Article:

$63.00 plus tax (Refund Policy)


Sphingolipids constitute a broad class of compounds with many biological functions. The sphingolipid metabolites ceramide and sphingosine are potent apoptosis inducers and produce cell cycle arrest, whereas sphingosine-1-phosphate promotes cellular growth and differentiation. Herein, the effects of sphingolipids and their analogs on diverse signaling pathways implicated in the apoptotic process are highlighted. The relatively simple chemical structure of these compounds has led to several strategies for their total synthesis. Those methods have contributed to the development and biological study of several analogs that present diverse degree of modification from the original structure. This article catalogues many of the recently developed synthetic analogs that act on diverse aspects of sphingolipid metabolism. A description of known enzyme inhibitors of the sphigolipids pathway is also given. Finally, diverse new sphingolipid-like antitumor agents isolated from marine sources are presented. This contribution opens the way for future development of new sphingolipid analogs that might be useful in cancer chemotherapy.

Keywords: Sphingolipid analogs; anticancer drugs; apoptosis; ceramide; drug design; signal transduction; sphingosine; structure-activity relationships

Document Type: Research Article


Affiliations: Instituto Canario de Investigacion del Cancer, Unidad de Investigacion, Hospital Universitario NS de Candelaria, Ctra. del Rosario s/n, 38010 S/C de Tenerife, Spain.

Publication date: 2006-03-01

More about this publication?
  • Current Medicinal Chemistry covers all the latest and outstanding developments in medicinal chemistry and rational drug design. Each issue contains a series of timely in-depth reviews written by leaders in the field covering a range of the current topics in medicinal chemistry. Current Medicinal Chemistry is an essential journal for every medicinal chemist who wishes to be kept informed and up-to-date with the latest and most important developments.
  • Access Key
  • Free ContentFree content
  • Partial Free ContentPartial Free content
  • New ContentNew content
  • Open Access ContentOpen access content
  • Partial Open Access ContentPartial Open access content
  • Subscribed ContentSubscribed content
  • Partial Subscribed ContentPartial Subscribed content
  • Free Trial ContentFree trial content
Cookie Policy
Cookie Policy
Ingenta Connect website makes use of cookies so as to keep track of data that you have filled in. I am Happy with this Find out more